Table 5.

Multivariate cox-proportional hazard analysis of 3-yr events, based on RAS inhibitor prescription at discharge (N = 12,200).

Events	With RAS inhibitors (N = 9729)	Without RAS inhibitors (N = 2471)	Hazard ratio* (95% CI)	P value
	No. of patients with events (rate per 100 patient-year†)
Cardiac death	465 (1.8)	180 (2.9)	0.82 (0.68–0.99)	.039
All-cause death	761 (2.9)	275 (4.4)	0.85 (0.74–0.99)	.034
MI	319 (1.2)	78 (1.3)	1.04 (0.80–1.35)	.785
Revascularization	832 (3.4)	214 (3.6)	0.90 (0.77–1.05)	.165
Heart failure‡	344 (1.3)	116 (1.9)	0.87 (0.70–1.09)	.231
MACE	1540 (6.4)	468 (8.1)	0.88 (0.79–0.98)	.024
Stroke	204 (0.8)	49 (0.8)	1.07 (0.77–1.48)	.699
MACCE	1699 (7.1)	505 (8.8)	0.90 (0.81–0.996)	.042
NCD	291 (1.1)	95 (1.5)	0.91 (0.71–1.17)	.459
MACE with NCD	1794 (7.4)	547 (9.5)	0.89 (0.80–0.98)	.021

Abbreviations: CI = confidence interval, MACCE = major adverse cardiocerebral event, MACE = major adverse cardiac event, MI = myocardial infarction, NCD = noncardiac death.

^*Adjusted for age, sex, body mass index, hypertension, diabetes mellitus, prior angina, prior MI, prior heart failure, current smoker status, Killip class, estimated glomerular filtration rate, left ventricular ejection fraction, type of myocardial infarction, coronary reperfusion, and medications at discharge (aspirin, P2Y12 inhibitors, beta-blockers, and statins).

^†Unadjusted event rate.

^‡Re-hospitalization due to heart failure.